Immunization News and Research RSS Feed - Immunization News and Research

Analyzing potential TB vaccine

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats. [More]
Measles vaccination plays key role in reducing child mortality

Measles vaccination plays key role in reducing child mortality

The number of measles-related deaths has decreased 79% from 546 800 at the beginning of the century to 114 900 in 2014. New data released by WHO for the Measles & Rubella Initiative, estimates that 17.1 million lives have been saved since 2000, largely due to increased vaccination coverage against this highly contagious viral disease. [More]
GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue. [More]
New vaccine candidate shows great promise at fighting respiratory syncytial virus

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S. [More]
Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

The study showed that about thirty percent to maybe half of the leading causes of death in the world are preventable. These are risk factors that you could manage and thus you could prevent a lot of premature deaths. [More]
Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013. [More]
SAGE recommends pilot implementation of malaria vaccine to protect young children

SAGE recommends pilot implementation of malaria vaccine to protect young children

The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended pilot projects to understand how to best use a vaccine that protects against malaria in young children. [More]
Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21. [More]
Outreach program increases completion of HPV vaccination series by teens in safety-net settings

Outreach program increases completion of HPV vaccination series by teens in safety-net settings

A joint study by UT Southwestern Medical Center and Parkland Health & Hospital System investigators found that a multicomponent outreach program increased completion of the three-dose human papillomavirus (HPV) vaccination series that reduces the risk of cervical cancer caused by the virus. [More]
U.S. News and World Report names MU Health Care as a 'Most Connected Hospital'

U.S. News and World Report names MU Health Care as a 'Most Connected Hospital'

University of Missouri Health Care has been named a "Most Connected Hospital" by U.S. News and World Report for using health information innovations to improve patient care. MU Health Care is one of two health systems in Missouri to make the 2015-2016 list released today, Friday, Oct. 16. [More]
High dose flu vaccines significantly reduce hospitalization risk during influenza season

High dose flu vaccines significantly reduce hospitalization risk during influenza season

In the largest nursing home study to date on the effect of high dose flu vaccine, researchers found that shots with four times the strength of standard flu shots significantly reduced the risk of being hospitalized during the influenza season. There was a 1.2 percent difference (19.7 percent versus 20.9 percent) in admission for the group that received the high dose vaccine compared to the one that received the standard dose vaccine. [More]
Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

More than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination, according to a study led by investigators at Vanderbilt University Medical Center, published this week in the Journal of the American Medical Association. [More]
MU Health Care wins global HIMSS Enterprise Nicholas E. Davies Award of Excellence

MU Health Care wins global HIMSS Enterprise Nicholas E. Davies Award of Excellence

University of Missouri Health Care has received the global HIMSS Enterprise Nicholas E. Davies Award of Excellence for health care technology innovations that are improving patient outcomes. [More]

Patients with influenza-associated pneumonia less likely to receive influenza vaccine: Study

Among children and adults hospitalized with community-acquired pneumonia, those with influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received an influenza vaccination, according to a study published online by JAMA. [More]
Polio no more in Nigeria, WHO says

Polio no more in Nigeria, WHO says

The World Health Organization announced today that polio is no longer endemic in Nigeria. This is the first time that Nigeria has interrupted transmission of wild poliovirus, bringing the country and the African region closer than ever to being certified polio-free. [More]
Polio no more in Nigeria, WHO says

Polio no more in Nigeria, WHO says

WHO announced today that polio is no longer endemic in Nigeria. This is the first time that Nigeria has interrupted transmission of wild poliovirus, bringing the country and the African region closer than ever to being certified polio-free. [More]
Optum and AMGF launch pilot collaborative to enhance adult vaccination rates

Optum and AMGF launch pilot collaborative to enhance adult vaccination rates

The American Medical Group Foundation (AMGF) and Optum, with support from Pfizer, are launching a pilot collaborative to improve adult vaccination rates. [More]
WHO and the Government of Saudi Arabia work together to care for health issues of hajj pilgrims

WHO and the Government of Saudi Arabia work together to care for health issues of hajj pilgrims

As an estimated 2 million Muslims from 184 countries gather in Saudi Arabia’s holy city of Mecca to take part in the annual hajj pilgrimage, months of preparations to care for health issues of pilgrims are also coming together. [More]
ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States. [More]
CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines. [More]
Advertisement
Advertisement